Overtime work is bad for the heart

Working overtime is bad for the heart according to results from a long-running study following more than 10,000 civil servants in London (UK): the Whitehall II study.read...

Compound could become important new antidepressant

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the...

Targacept gets $200M payment from AstraZeneca

Targacept has received a hefty $200 million milestone payment from AstraZeneca. The money is part of a deal signed in December that could be worth up to $1.2 billion. Targacept is developing TC-5214, a drug for major depressive disorder (MDD), which is headed into Phase III trials this year. The milestone payment was triggered by the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Targacept and AstraZeneca hope to file an NDA for TC-5214 as a...

Few Americans with major depression receive adequate treatment

Many US adults with major depression do not receive treatment for depression or therapy based on treatment guidelines, and some racial and ethnic groups have even lower rates of adequate depression care, according to a new...

Increased risk of death, stroke in postmenopausal women taking antidepressants, study finds

Women participating in the Women's Health Initiative study who reported taking an antidepressant drug had a small but statistically significant increase in the risk of stroke and of death compared with participants not taking antidepressants. The authors of the study note that their findings are not conclusive but may signify a need for additional attention to patients' cardiovascular risk...

Earlier bedtimes may help protect adolescents against depression and suicidal thoughts

New research finds that adolescents with bedtimes that were set earlier by parents were significantly less likely to suffer from depression and to think about committing suicide, suggesting that earlier bedtimes could have a protective effect by lengthening sleep duration and increasing the likelihood of getting enough...

Naurex’ GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA...